Curis Inc (CRIS) News Headlines

▮ More

Date

Headline

5/5/2022 4:06:08 PM Curis Q1 Loss/share $0.18 Vs. Loss $0.11 Year Ago

5/5/2022 4:03:46 PM Curis Inc Q1 Loss increases, misses estimates

4/11/2022 8:16:12 AM Curis: FDA Places Partial Clinical Hold On TakeAim Lymphoma Study - Quick Facts

4/11/2022 8:03:07 AM Curis Announces FDA Partial Clinical Hold For TakeAim Lymphoma Study Of Emavusertib On B-cell Malignancies

4/4/2022 7:22:05 AM Curis Reports Partial Clinical Hold On TakeAim Leukemia Phase 1/2a Study

4/4/2022 7:04:29 AM Pre-market Movers: ISAA, TWTR, GTIM, SPI, IVDA…

4/4/2022 7:04:19 AM Curis Announces FDA Places Partial Clinical Hold For TakeAim Leukemia Study Of Emavusertib

2/24/2022 4:06:26 PM Curis Reports Q4 Loss Per Share Of $0.15 Vs. Loss Per Share Of $0.11 Last Year

2/24/2022 4:04:29 PM Curis Inc Q4 Loss increases, misses estimates

2/24/2022 3:02:34 PM Curis Q4 21 Earnings Conference Call At 4:30 PM ET

1/10/2022 6:00:10 AM Curis To Present At H.C. Wainwright BioConnect Conference; Webcast At 7:00 AM ET

1/6/2022 10:59:07 AM Curis Shares Down 27%

1/6/2022 7:05:22 AM Curis Reports Data With Addl Clinical Activity In Phase 1/2 Study Of CA-4948 Monotherapy In Relapsed/Refractory AML,MDS

11/9/2021 4:03:39 PM Curis Inc Q3 Earnings Summary

11/9/2021 4:03:01 PM Curis Q4 Loss/share $0.12 Vs. Loss $0.11 Year Ago

11/9/2021 3:00:09 PM Curis Q3 21 Earnings Conference Call At 4:30 PM ET

11/9/2021 8:03:05 AM Curis Announces New Preclinical Data For CI-8993 At The Society For Immunotherapy Of Cancer

11/8/2021 8:04:48 AM Curis Says First Patient Dosed In Phase 1/2 Study Of CA-4948 In Patients With Refractory Acute Myeloid Leukemia

10/7/2021 9:10:23 AM Curis Presents Data Highlights Potential Of CA-4948 In Multiple Hematologic Malignancies On Molecular Targets

8/3/2021 4:07:17 PM Curis Reports Q2 Loss Per Share Of $0.12 Vs. $0.17 Last Year